| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Centella asiatica / Gotu kola → AsiaticosideCentella asiatica, commonly known as Gotu kola, is a medicinal botanical used mainly for wound healing, skin repair, microcirculation support, anti-inflammatory effects, and possible neuroprotective activity.
Asiaticoside is one of the major active and marker compounds in Centella asiatica.
Structure: Centella asiatica / Gotu kola → Asiaticoside → Madecassoside → Asiatic acid → Madecassic acid Centella asiatica / Gotu kola → asiaticoside — Centella asiatica is a medicinal botanical extract source, and asiaticoside is one of its major pentacyclic triterpenoid saponin marker constituents. The formal classification is botanical standardized extract / natural-product triterpenoid saponin modality, not an approved anticancer drug. The principal active family includes asiaticoside, madecassoside, asiatic acid, and madecassic acid; asiaticoside can also be metabolically linked to asiatic acid. Asiaticoside as the main active marker, with Centella asiatica standardized extract as the primary product. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral translation is constrained by variable extract composition, limited dissolution and bioavailability of triterpenes, metabolism of glycosides to aglycones, and formulation dependence. Standardized extracts such as ECa 233 and aqueous Centella asiatica products have human phase-1 PK data, but systemic exposure is still not equivalent to common high-concentration in-vitro cancer experiments. In-vitro vs systemic exposure relevance: Cancer-cell studies commonly use micromolar asiaticoside or asiatic-acid exposures that may exceed or not cleanly map onto achievable plasma exposure after oral botanical dosing. Topical and local tissue uses are more plausible for skin/wound biology than systemic anticancer effects. For cancer translation, the entry should be treated as concentration- and formulation-dependent. Clinical evidence status: Cancer relevance is weak / preclinical only, with no established oncology indication. Human evidence is stronger for wound healing, venous/skin-related uses, and early cognitive/AD-oriented safety or PK studies than for cancer treatment. AD relevance is possible / early clinical, with phase-1 target-engagement work in mild cognitive impairment or mild Alzheimer’s disease, but no proven disease-modifying efficacy. Centella asiatica and Asiaticoside Mechanistic Profile
P: 0–30 min R: 30 min–3 hr G: >3 hr AD relevance: Possible / preclinical. Interest is mainly through neuroinflammation, oxidative stress, mitochondrial protection, and general neuroprotective mechanisms. Alzheimer’s disease relevance: Centella asiatica / Gotu kola has a plausible but unproven AD-oriented profile. The strongest rationale is not direct amyloid clearance as an established clinical effect, but combined modulation of neuroinflammation, oxidative stress, mitochondrial metabolism, synaptic or neuronal viability markers, and vascular/microcirculatory support. Human evidence is early: phase-1 PK/safety and target-engagement studies exist in older adults with mild cognitive impairment or mild Alzheimer’s disease, but efficacy remains unproven. Clinical evidence status: AD / cognition evidence is preclinical plus small human and phase-1 clinical work. Early translational / investigational rather than established therapy. Cancer relevance: Weak / preclinical. AD-Oriented Mechanistic Profile
|
| Source: CGL-Driver Genes |
| Type: TSG |
| NOTCH1 is a gene that encodes a protein involved in the Notch signaling pathway, which plays a crucial role in cell differentiation, proliferation, and apoptosis. Overall, the expression of NOTCH1 in cancer is complex and can have different implications depending on the tumor type and microenvironment. Notch1 is a transmembrane receptor involved in the Notch signaling pathway, a highly conserved mechanism that regulates cell differentiation, proliferation, and apoptosis. – Activation occurs following interaction with membrane-bound ligands (e.g., Jagged and Delta-like proteins) on adjacent cells, leading to proteolytic cleavage and release of the Notch intracellular domain (NICD). Notch1 expression can be upregulated or activated in many types of cancers, including T‑cell acute lymphoblastic leukemia (T‑ALL), breast cancer, and certain solid tumors. – In other contexts, such as in some squamous cell carcinomas and cancers of the colon, Notch1 signaling can be reduced, suggesting a dual role depending on the tissue of origin and tumor microenvironment. |
| 6650- | Cen, | Therapeutic Potential of Centella asiatica and Its Triterpenes: A Review |
| - | Review, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:417 Target#:221 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid